AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2016
Nov 18, 2016
30583_dirs_2016-11-18_d37c0ce0-ee86-4e59-8aa1-c1b2e0b83135.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2016-11-16
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-11-16 | Common Stock | M | 41670 | $17.54 | Acquired | 365038 | Direct |
| 2016-11-16 | Common Stock | S | 41670 | $90.9718 | Disposed | 323368 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-11-16 | Stock Option (right to buy Common Stock) | $17.54 | M | 41670 | Disposed | 2016-11-19 | Common Stock (41670) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 25758 | Indirect |
Footnotes
F1: Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F2: The price in column 4 is the weighted average price. The price actually received ranged from $90.00 to $92.22. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.